Al Saran Khalid, Sabry Alaa
Prince Salman Center for Kidney Diseases, Riyadh, Saudi Arabia.
Saudi J Kidney Dis Transpl. 2012 Jan;23(1):78-82.
To assess the cost of hemodialysis (HD) delivered at our center according to the treatment protocols based on the current Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines, we analyzed our cost data during the period from 1st of January 2007 to 30th of June 2010. The methods were used to determine both direct costs (related to dialysis treatment such as dialysis disposables, dialysis related drugs, medical personnel, out-patient medications, laboratory and other ancillary services) and overhead costs (building, maintenance and engineering costs, housekeeping, and administrative personnel). During the study period, an average of 2,500 HD sessions per month were performed for 200 patients. The mean total cost per HD session was calculated as 297 US dollars (USD) [1,114 Saudi Riyals (SR)], and the mean total cost of dialysis per patient per year was 46,332 USD (173,784 SR). Direct costs contributed to 81.15% of the total cost from which the personnel cost represented 41.11% and dialysis disposables represented 13.64%, while medications (outpatient and intravenous dialysis related medications including albumin, erythropoiesis stimulating agents, iron and vitamin D₃) accounted for 12.47% of the total cost. Our total cost level is well below the average cost in the industrialized countries.
为根据当前肾脏病预后质量倡议（K/DOQI）指南的治疗方案评估我们中心提供的血液透析（HD）成本，我们分析了2007年1月1日至2010年6月30日期间的成本数据。所采用的方法用于确定直接成本（与透析治疗相关的成本，如透析耗材、透析相关药物、医务人员、门诊用药、实验室及其他辅助服务）和间接费用（建筑、维护和工程成本、家政和行政人员）。在研究期间，每月平均为200名患者进行2500次HD治疗。每次HD治疗的平均总成本计算为297美元（USD）[1114沙特里亚尔（SR）]，每位患者每年的透析平均总成本为46332美元（173784 SR）。直接成本占总成本的81.15%，其中人员成本占41.11%，透析耗材占13.64%，而药物（门诊和静脉透析相关药物，包括白蛋白、促红细胞生成素、铁和维生素D₃）占总成本的12.47%。我们的总成本水平远低于工业化国家的平均成本。
